Summary of Royalty Pharma Investor Day Company Overview - **Company**: Royalty Pharma (NasdaqGS:RPRX) - **Industry**: Biopharma royalty market - **Event Date**: September 11, 2025 - **Key Leadership**: George Brofic (Investor Relations), Pablo (CEO), Ashwin (EVP), Chris (EVP), Marshall, Brienne, Terry Core Messages and Financial Performance - **Execution of Strategy**: Royalty Pharma has successfully executed its strategy since its IPO in 2020, delivering strong growth and returns in the rapidly expanding royalty market [21][23][24] - **Market Growth**: The biopharma royalty market has more than doubled in size since 2020, with expectations for continued growth driven by increasing capital needs in the biopharma sector [24][34] - **Financial Targets**: The company is on track to achieve a compounded annual growth rate (CAGR) of 12% in top line revenue since 2020, with a target of at least $4.7 billion by 2030 [26][28][59] - **Capital Deployment**: Royalty Pharma has deployed approximately $14 billion in capital on new royalty transactions since 2020, generating a 15% return on invested capital [26][29] Competitive Advantages - **Business Model**: Royalty Pharma has refined its business model over nearly 30 years, positioning itself as the optimized buyer of royalties, with a focus on delivering win-win solutions for partners [24][39] - **Investment Approach**: The company employs a rigorous investment process, historically transacting on only 2% of initial reviews, and maintains a healthy balance between approved and development stage investments [42][44] - **Risk Mitigation**: Royalty Pharma focuses on low-risk opportunities, with 90% of its royalty investments since 2020 projected to exceed its cost of capital [43][46] Industry Dynamics - **Funding Role of Royalties**: Royalties are increasingly recognized as a critical funding source for biopharma, offering flexibility and non-dilutive capital compared to traditional debt and equity [30][31] - **Market Demand**: The total addressable market for funding in biopharma is projected to exceed $1 trillion over the next decade, driven by high capital needs and the increasing number of licensing deals [34][88] - **Megatrends**: Key trends include rapid scientific innovation, R&D fragmentation, and significant capital requirements in the biopharma sector, all contributing to the growth of the royalty market [82][84][88] Survey Insights - **Deloitte Study**: A recent survey by Deloitte indicates that 87% of biotech executives would consider using royalties for financing, highlighting the growing acceptance and strategic importance of royalties in the capital structure [67][71] - **Executive Perspectives**: The survey revealed that two-thirds of executives cited the lack of equity dilution as a key benefit of royalties, with many expressing increased interest in royalty financing over the past three years [68][71] Philanthropic Efforts - **Community Engagement**: Royalty Pharma emphasizes its commitment to philanthropy and public service, supporting health equity, STEM education, and community initiatives [63][64] Conclusion - **Future Outlook**: Royalty Pharma is positioned for strong value creation, with a best-in-class investment platform and a commitment to delivering mid-teens annualized total shareholder returns over the next five years [60][63]